Skip to main navigation
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Contact
  • Programs
    • HBV
    • Pipeline
  • Patients
    • Commitment
    • Clinical Trials
    • Resources
  • Sustainability
    • Overview
    • Business Ethics
    • Access to Health Care
    • Human Capital
    • Environment, Health and Safety
  • Collaborations
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
  • Careers
    • Culture
    • Benefits
    • Opportunities
On the

Investor Relations

Corporate Profile

Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

See all news
  • Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
  • Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
  • Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

Events &
Presentations

See all upcoming events
  • Nov 15, 2022 at 12:35 PM EST
    Jefferies London Healthcare Conference – Fireside Chat
  • Nov 4 - Nov 8, 2022
    AASLD – The Liver Meeting 2022
  • Oct 18, 2022 from 12:00 PM to 12:30 PM EDT
    H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Virtual Conference
Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds
Search Investors

Contact Us

833.509.4583
info@assemblybio.com
LinkedIn
About Programs Patients Collaborations Investors Careers

© 2023 Assembly Biosciences, Inc.